1-[4-(1-methyl-1,2,3,6-tetrahydro-5-pyridinyl)-1,2,5-thiadiazol-3-yloxy]-2-[2-(2-{2-[4-(1-methyl-1,2,3,6-tetrahydro-5-pyridinyl)-1,2,5-thiadiazol-3-yloxy]ethoxy}ethoxy)ethoxy]ethane

ID: ALA335542

Chembl Id: CHEMBL335542

PubChem CID: 9809330

Max Phase: Preclinical

Molecular Formula: C24H36N6O5S2

Molecular Weight: 552.72

Molecule Type: Small molecule

Names and Identifiers

Synonyms: CDD-0273 | CHEMBL335542|SCHEMBL4030575|CDD-0273|BDBM50107697|L020961|1-[4-(1-methyl-1,2,3,6-tetrahydro-5-pyridinyl)-1,2,5-thiadiazol-3-yloxy]-2-[2-(2-{2-[4-(1-methyl-1,2,3,6-tetrahydro-5-pyridinyl)-1,2,5-thiadiazol-3-yloxy]ethoxy}ethoxy)ethoxy]ethane|1-methyl-5-(4-(2-(2-(2-(2-(4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yloxy)ethoxy)ethoxy)ethoxy)ethoxy)-1,2,5-thiadiazol-3-yl)-1,2,3,6-tetrahydropyridine

Canonical SMILES:  CN1CCC=C(c2nsnc2OCCOCCOCCOCCOc2nsnc2C2=CCCN(C)C2)C1

Standard InChI:  InChI=1S/C24H36N6O5S2/c1-29-7-3-5-19(17-29)21-23(27-36-25-21)34-15-13-32-11-9-31-10-12-33-14-16-35-24-22(26-37-28-24)20-6-4-8-30(2)18-20/h5-6H,3-4,7-18H2,1-2H3

Standard InChI Key:  NHUURXLCGOCXHZ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA335542

   1-Methyl-5-(4-(2-(2-(2-(2-(4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yloxy)ethoxy)ethoxy)ethoxy)ethoxy)-1,2,5-thiadiazol-3-yl)-1,2,3,6-tetrahydropyridine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 552.72

Molecular Weight (Monoisotopic): 552.2189

AlogP: 2.33

#Rotatable Bonds: 16

Polar Surface Area: 104.19

Molecular Species: NEUTRAL

HBA: 13

HBD: ┄

#RO5 Violations: 2

HBA (Lipinski): 11

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): 2

CX Acidic pKa: ┄

CX Basic pKa: 7.00

CX LogP: 2.80

CX LogD: 2.64

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.29

Np Likeness Score: -0.44

References

1. Cao Y, Zhang M, Wu C, Lee S, Wroblewski ME, Whipple T, Nagy PI, Takács-Novák K, Balázs A, Torös S, Messer WS..  (2003)  Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders.,  46  (20): [PMID:13678406] [10.1021/jm0301235]

2. Rajeswaran WG, Cao Y, Huang XP, Wroblewski ME, Colclough T, Lee S, Liu F, Nagy PI, Ellis J, Levine BA, Nocka KH, Messer WS..  (2001)  Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists.,  44  (26): [PMID:11741475] [10.1021/jm0102405]

3. Tejada FR, Nagy PI, Xu M, Wu C, Katz T, Dorsey J, Rieman M, Lawlor E, Warrier M, Messer WS..  (2006)  Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the binding and activity at muscarinic receptor subtypes and chimeras.,  49  (25): [PMID:17149881] [10.1021/jm0606995]

Source

Source(1):

• Scientific Literature